Key facts
- Immusoft’s last known valuation is $65.2M (Mar 2025).
- It has raised $54.8M across 6 recorded rounds; the latest was Seed Round ($4.6M) in May 2024.
- Notable investors include Founders Fund, Alexandria Venture Investments, Highlight Capital, Invariantes Fund, GRIDS Capital — 29 tracked in total.
- Immusoft has filed 8 Form Ds with the SEC since 2014, most recently Jun 2024 ($4.6M sold to 25 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 29 names
- ·Watchlist + deal alerts for Immusoft
Funding rounds
6 roundsAbout Immusoft
Developer of novel therapies designed for the treatment of rare diseases. The company develops autologous cell therapies based on its immune system programming technology that entails collecting a type of the patient's immune cells, called B cells which can turn into bio factories each of which manufactures and secretes various antibodies, enabling the medical community to combat infectious diseases.
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2009
- Employees
- 22
- Website
- immusoft.com/
- Ownership
- Privately Held (backing)
Immusoft doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Immusoft shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Immusoft in its N-PORT filings yet. We sweep new filings monthly.